Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.
Metastatic Colorectal Cancer|Hepatocellular Carcinoma
DRUG: Enfortumab Vedotin
Overall response rate (ORR), The ORR is defined as the proportion of evaluable patients with confirmed CR or PR according to RECIST v1.1., Up to 3 years
Duration of Response (DOR), The DOR is defined as the time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD (per RECIST v1.1) or to death due to any cause, whichever comes first., Up to 3 years|Progression-free Survival (PFS), PFS is defined as the time from start of study treatment to first documentation of objective tumor progression (PD per RECIST v1.1), or to death due to any cause, whichever comes first., Up to 3 years|Overall Survival (OS), OS is defined as the time from start of study treatment to date of death due to any cause., Up to 3 years
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.